Drugs / Sup19 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07539610 | Apr 2026 → Nov 2027 expected | B-cell acute lymphoblastic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sup19 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07539610 ↗ |
| Modality | Cell therapy | “Sup19 CAR-T cells” NCT07539610 ↗ |